Here's the live share price of Lyka Labs along with daily highs, lows, percentage changes and volume trends, and, all financial information.
Over the last 5 years, the share price of Lyka Labs has gained 29.01% CAGR. Over the past year, the corresponding return has been -49.33%.
Lyka Labs’s current P/E of 133.03x helps give context to how the market is valuing the stock based on recent earnings and growth expectations.
Name | 1W(%) | 1M(%) | 3M(%) | 6M(%) | 1Y(%) | 3Y(%) | 5Y(%) |
|---|---|---|---|---|---|---|---|
| Lyka Labs | 3.38 | -4.96 | -22.85 | -32.55 | -48.84 | -17.02 | 29.01 |
| Sun Pharmaceutical Industries | -2.22 | -1.46 | 7.89 | 5.65 | -3.43 | 20.52 | 25.03 |
| Divi's Laboratories | 2.83 | 1.78 | 8.17 | -1.43 | 11.90 | 22.78 | 11.90 |
| Torrent Pharmaceuticals | 1.14 | 2.52 | 5.45 | 19.97 | 12.08 | 34.70 | 22.19 |
| Cipla | 0.23 | -0.23 | -2.44 | -0.16 | 1.66 | 10.29 | 12.73 |
| Dr. Reddy's Laboratories | 0.81 | 4.70 | -1.30 | -4.12 | -5.10 | 14.14 | 4.19 |
| Lupin | -0.11 | 5.61 | 6.01 | 9.33 | -2.65 | 40.78 | 16.99 |
| Zydus Lifesciences | 1.49 | 0.58 | -9.97 | -3.41 | -3.36 | 30.41 | 14.44 |
| Mankind Pharma | 5.69 | 0.47 | -11.82 | -3.37 | -23.37 | 16.13 | 9.39 |
| Aurobindo Pharma | 1.89 | 1.78 | 11.37 | 10.11 | -3.70 | 40.57 | 6.44 |
| Alkem Laboratories | -0.87 | -0.88 | 0.04 | 16.07 | 3.12 | 22.46 | 14.22 |
| Abbott India | 2.38 | -4.72 | -6.08 | -10.12 | -0.50 | 9.13 | 12.41 |
| Laurus Labs | 6.22 | 9.32 | 17.92 | 60.16 | 89.02 | 40.80 | 25.52 |
| Glenmark Pharmaceuticals | 5.08 | 11.16 | 1.43 | 21.68 | 33.23 | 68.34 | 32.84 |
| Biocon | 3.78 | 1.61 | 11.75 | 14.93 | 16.30 | 14.50 | -3.69 |
| GlaxoSmithKline Pharmaceuticals | -3.36 | 0.81 | -9.21 | -22.69 | 10.15 | 23.13 | 10.31 |
| Anthem Biosciences | 0.41 | 5.58 | -18.80 | -8.67 | -8.67 | -2.98 | -1.80 |
| Ipca Laboratories | 2.71 | 0.97 | 6.21 | 7.49 | -9.34 | 18.38 | 5.88 |
| Ajanta Pharma | 2.00 | 5.50 | 4.77 | 3.36 | -5.37 | 28.86 | 19.56 |
| J B Chemicals & Pharmaceuticals | 0.50 | 2.89 | 6.36 | 0.23 | -3.36 | 22.71 | 28.10 |
Over the last one year, Lyka Labs has declined 48.84% compared to peers like Sun Pharmaceutical Industries (-3.43%), Divi's Laboratories (11.90%), Torrent Pharmaceuticals (12.08%). From a 5 year perspective, Lyka Labs has outperformed peers relative to Sun Pharmaceutical Industries (25.03%) and Divi's Laboratories (11.90%).
| Day | SMA | EMA |
|---|---|---|
| 5 | 75.09 | 76.01 |
| 10 | 76.39 | 76.55 |
| 20 | 78.75 | 78.58 |
| 50 | 86.56 | 84.67 |
| 100 | 93.79 | 92.04 |
| 200 | 102.44 | 102.03 |
In the latest quarter, Lyka Labs remained same as its previous close in promoter holding, while DII stake unchanged at 0.66%, FII holding rose to 0.17%, and public shareholding moved down to 40.99% compared to the previous quarter — reflecting a shift in investor sentiment across categories.
Date Time | Announcement |
|---|---|
| Dec 22, 2025, 9:40 PM IST | Lyka Labs - Update On The Scheme Of Amalgamation |
| Dec 05, 2025, 9:38 PM IST | Lyka Labs - Update On The Scheme Of Amalgamation |
| Nov 12, 2025, 8:08 PM IST | Lyka Labs - Financial Results For The Quarter 30Th September 2025 |
| Nov 12, 2025, 8:04 PM IST | Lyka Labs - Board Meeting Outcome for Outcome Of The Board Meeting Held On 12Th November, 2025 |
| Nov 08, 2025, 9:25 PM IST | Lyka Labs - Update On The Scheme Of Amalgamation |
Lyka Labs Ltd. is a Public Limited Listed company incorporated on 29/12/1976 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ1976PLC008738 and registration number is 008738. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 134.70 Cr. and Equity Capital is Rs. 35.69 Cr. for the Year ended 31/03/2025.
The share price of any company is dynamic and keeps changing depending on the trade initiated. The shares have a fixed opening rate and closing rate. The share price for Lyka Labs is ₹76.49 as on Dec 23, 2025.
The Lyka Labs is operating in the Pharmaceuticals and health care Sector. It is classified as a Smallcap stock on the BSE.
The market cap of Lyka Labs is ₹272.99 Cr as on Dec 23, 2025.
Today’s highest and lowest price of Lyka Labs are ₹77.44 and ₹76.41.
The 52-week high/low is the highest and lowest price at which Lyka Labs stock has traded in the past 52-week or nearly a year. The 52-week high of Lyka Labs is ₹167.10 and 52-week low of Lyka Labs is ₹73.56 as on Dec 23, 2025.
The Lyka Labs has shown returns of 0.38% over the past day, -4.96% for the past month, -23.39% over 3 months, -49.33% over 1 year, -17.02% across 3 years, and 29.01% over 5 years.
P/E ratio of and PB ratio of Lyka Labs are 133.03 and 2.70 on Dec 23, 2025. While the company gives a dividend yield of 0.00 per annum.